HomeCompareAYYLF vs JNJ

AYYLF vs JNJ: Dividend Comparison 2026

AYYLF yields 1.72% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AYYLF wins by $3.2K in total portfolio value
10 years
AYYLF
AYYLF
● Live price
1.72%
Share price
$8.80
Annual div
$0.15
5Y div CAGR
28.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.5K
Annual income
$3,335.28
Full AYYLF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AYYLF vs JNJ

📍 AYYLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAYYLFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AYYLF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AYYLF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AYYLF
Annual income on $10K today (after 15% tax)
$146.09/yr
After 10yr DRIP, annual income (after tax)
$2,834.99/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $1,151.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AYYLF + JNJ for your $10,000?

AYYLF: 50%JNJ: 50%
100% JNJ50/50100% AYYLF
Portfolio after 10yr
$31.9K
Annual income
$4,012.34/yr
Blended yield
12.59%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AYYLF
No analyst data
Altman Z
0.9
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AYYLF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAYYLFJNJ
Forward yield1.72%2.13%
Annual dividend / share$0.15$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR28.9%28%
Portfolio after 10y$33.5K$30.3K
Annual income after 10y$3,335.28$4,689.40
Total dividends collected$11.7K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AYYLF vs JNJ ($10,000, DRIP)

YearAYYLF PortfolioAYYLF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,922$221.55$10,592$272.30+$330.00AYYLF
2$11,978$291.49$11,289$357.73+$689.00AYYLF
3$13,201$385.10$12,123$472.89+$1.1KAYYLF
4$14,636$511.31$13,141$629.86+$1.5KAYYLF
5$16,344$682.93$14,408$846.81+$1.9KAYYLF
6$18,407$918.69$16,021$1,151.60+$2.4KAYYLF
7$20,942$1,246.40$18,122$1,588.22+$2.8KAYYLF
8$24,116$1,708.28$20,930$2,228.20+$3.2KAYYLF
9$28,174$2,369.84$24,792$3,191.91+$3.4KAYYLF
10$33,481$3,335.28$30,274$4,689.40+$3.2KAYYLF

AYYLF vs JNJ: Complete Analysis 2026

AYYLFStock

Ayala Corporation engages in the real estate and hotel businesses in the Philippines and internationally. Its Real Estate and Hotels segment develops, constructs, leases, and sells residential and commercial communities; manages land bank; operates hotels, cinema, and theaters; and provides construction and property management services. The company's Financial Services and Insurance segment provides corporate, consumer, mortgage, leasing, and agri loans; deposit and cash management, asset management, online stock trading, foreign exchange and capital markets investments dealing, corporate finance and consulting, investment banking, internet banking, foreign exchange, and safety deposit services; and life, non-life, pre-need, and reinsurance services. Its Telecommunications segment offers digital wireless communication, long distance communication, broadband internet, wireline voice and data communication, and local exchange carrier services; and designs, develops, operates, administers, and manages software applications and systems. The company's Water segment manages, operates, repairs, decommissions, and refurbishes fixed and movable assets required to provide water delivery, sewerage, and sanitation, distribution, pipe works, used water management, and management services. Its Industrial Technologies segment offers electronics manufacturing, and power semiconductor assembly and testing services. The company's Power segment generates power using renewable and conventional technologies. Its Automotive, Outsourcing and Others segment manufactures, distributes, sells, repairs, and services passenger cars and commercial vehicles; provides venture capital for technology businesses; onshore and offshore outsourcing, air-chartered, consultancy, agri-business, education, human capital resource management, and health services; and invests in property companies and other projects. Ayala Corporation was founded in 1834 and is headquartered in Makati City, the Philippines.

Full AYYLF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AYYLF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AYYLF vs SCHDAYYLF vs JEPIAYYLF vs OAYYLF vs KOAYYLF vs MAINAYYLF vs ABBVAYYLF vs MRKAYYLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.